George Au-Yeung

Drug resistance in end-stage high-grade serous ovarian cancer.

Elizabeth L Christie, Kathryn Alsop, George Au-Yeung, Ahwan Pandey, David DL Bowtell

Conference Proceedings  |  2020  |  CLINICAL CANCER RESEARCH

Antiapoptotic gene expression and sensitivity to BH3-mimetics in chemoresistant, high-grade serous ovarian cancer cell lines.

Cristina Mapagu, Sivatharsny Srirangan, George Au-Yeung, Paul R Harnett, David D Bowtell, Anna deFazio

Conference Proceedings  |  2020  |  CLINICAL CANCER RESEARCH

Evaluating the impact of dose reductions and delays on progression-free survival in women with ovarian cancer treated with either three-weekly or dose-dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort study

T Sivakumaran, L Mileshkin, P Grant, L Na, A DeFazio, M Friedlander, A Obermair, PM Webb, G Au-Yeung

Journal article  |  2020  |  Gynecologic Oncology

OBJECTIVES: To determine the impact of chemotherapy dose reductions and dose delays on progression-free survival (PFS) in women wi..

FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment

Amir Iravani, Medhat M Osman, Alison M Weppler, Roslyn Wallace, Anna Galligan, Arian Lasocki, Morgan O Hunter, Tim Akhurst, Michael S Hofman, Peter KH Lau, Damien Kee, George Au-Yeung, Shahneen Sandhu, Rodney J Hicks

Journal article  |  2020  |  European Journal of Nuclear Medicine and Molecular Imaging

PURPOSE: We aimed to investigate the role of FDG-PET/CT in monitoring of response and immune-related adverse events (irAEs) follow..

i-Move, a personalised exercise intervention for patients with advanced melanoma receiving immunotherapy: a randomised feasibility trial protocol

Amelia Hyatt, Karla Gough, Andrew Murnane, George Au-Yeung, Tamara Dawson, Elizabeth Pearson, Haryana Dhillon, Shahneen Sandhu, Narelle Williams, Elizabeth Paton, Alex Billett, Anya Traill, Hayley Andersen, Victoria Beedle, Donna Milne

Journal article  |  2020  |  BMJ Open

INTRODUCTION: There is increasing evidence demonstrating the benefits of exercise in counteracting cancer treatment-related fatigu..

Efficacy of immune checkpoint inhibitors for in-transit melanoma

Emilia Nan Tie, Julia Lai-Kwon, Michael Alexander Rtshiladze, Lumine Na, James Bozzi, Tavis Read, Victoria Atkinson, George Au-Yeung, Georgina Long, Grant A McArthur, Shahneen Sandhu, Robyn Saw, Euan Walpole, Alexander Menzies, Mark Smithers, David E Gyorki

Journal article  |  2020  |  Journal for ImmunoTherapy of Cancer

BACKGROUND: The efficacy of immune checkpoint inhibitors (ICI) in metastatic melanoma is well established. However, there are limi..

A closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapies.

Christina W Guo, Marliese Alexander, Youseph Dib, Peter KH Lau, Alison M Weppler, George Au-Yeung, Belinda Lee, Chloe Khoo, Don Mooney, Subodh B Joshi, Louise Creati, Shahneen Sandhu

Journal article  |  2019  |  European Journal of Cancer

Immune checkpoint inhibitors (ICI) and tyrosine kinase inhibitors (TKI) have transformed the management of many malignancies. Alth..

Does physical activity improve chemotherapy completion in women receiving chemotherapy for ovarian cancer?

Vanessa L Beesley, Tanya L Ross, Nina Renhua Na, Tharani Sivakumaran, George Au-Yeung, Christina M Nagle, Anna deFazio, Peter Grant, Andreas Obermair, Michael Friedlander, Penelope Webb

Conference Proceedings  |  2019  |  ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY

Clinical and FDG-PET markers of immune checkpoint inhibitor (ICI) response in patients with metastatic Merkel cell carcinoma (mMCC)

AM Weppler, P Bhave, P De Ieso, M Chua, J Raleigh, A Hatzimihalis, A Gill, S Balachander, J Callahan, A Pattison, A Caneborg, G Au Yeung, G McArthur, RJ Hicks, R Tothill, SK Sandhu

Conference Proceedings  |  2019  |  ANNALS OF ONCOLOGY

Safety, antitumor activity, and pharmacokinetics (PK) of pamiparib (BGB-290), a PARP1/2 inhibitor, in patients (pts) with advanced solid tumours: Updated phase I dose-escalation/expansion results

M Voskoboynik, L Mileshkin, H Gan, M Millward, G Au-Yeung, TM Meniawy, G Kichenadasse, K Zhang, M Zhang, S Mu, JD Lickliter

Conference Proceedings  |  2019  |  ANNALS OF ONCOLOGY

The molecular origin and taxonomy of mucinous ovarian carcinoma

Dane Cheasley, Matthew J Wakefield, Georgina L Ryland, Prue E Allan, Kathryn Alsop, Kaushalya C Amarasinghe, Sumitra Ananda, Michael S Anglesio, George Au-Yeung, Maret Bohm, David Dl Bowtell, Alison Brand, Georgia Chenevix-Trench, Michael Christie, Yoke-Eng Chiew, Michael Churchman, Anna DeFazio, Renee Demeo, Rhiannon Dudley, Nicole Fairweather, et al.

Journal article  |  2019  |  NATURE COMMUNICATIONS

Clinical Utility of Real-Time Targeted Molecular Profiling in the Clinical Management of Ovarian Cancer: The ALLOCATE Study

Olga Kondrashova, Gwo-Yaw Ho, George Au-Yeung, Leakhena Leas, Tiffany Boughtwood, Kathryn Alsop, Giada Zapparoli, Alexander Dobrovic, Yi-An Ko, Arthur L Hsu, Clare J Love, Sebastian Lunke, Matthew J Wakefield, Orla McNally, Michael Quinn, Sumitra Ananda, Deborah Neesham, Anne Hamilton, Marisa Grossi, Alison Freimund, et al.

Journal article  |  2019  |  JCO Precision Oncology

Clinical and FDG-PET markers of immune checkpoint inhibitor (ICI) response in patients with metastatic Merkel cell carcinoma (mMCC).

Alison Weppler, Prachi Bhave, Paolo De Ieso, Jeanette Raleigh, Athena Hatzimihalis, Anthony J Gill, Shiva Balachander, Jason Callahan, Andrew Pattison, Margaret Chua, George Au-Yeung, Grant A McArthur, Rodney J Hicks, Richard Tothill, Shahneen Kaur Sandhu

Conference Proceedings  |  2019  |  Journal of Clinical Oncology

Efficacy of immune checkpoint inhibitors (ICIs) for in-transit melanoma.

Emilia Nan Tie, Julia Elizabeth Lai-Kwon, Lumine Na, Michael Alexander Rtshiladze, James Bozzi, Tavis Read, Victoria Atkinson, George Au-Yeung, Georgina V Long, Grant A McArthur, Shahneen Kaur Sandhu, Robyn Saw, Euan Thomas Walpole, Alexander M Menzies, B Mark Smithers, David E Gyorki

Conference Proceedings  |  2019  |  JOURNAL OF CLINICAL ONCOLOGY

Efficacy of immune checkpoint inhibitors (ICIs) for in-transit melanoma.

EN Tie, JE Lai-Kwon, L Na, MA Rtshiladze, J Bozzi, T Read, V Atkinson, G Au-Yeung, GV Long, GA McArthur, SK Sandhu, R Saw, ET Walpole, AM Menzies, BM Smithers, DE Gyorki

Journal article  |  2019  |  Journal of Clinical Oncology

Response assessment and immune-related adverse events as detected by FDG PET/CT in patients treated with combined CTLA-4 and PD-1 checkpoint inhibitors as first line therapy in advanced melanoma

Amir Iravani, Medhat Osman, Michael Hofman, Alison Weppler, George Au-Yeung, Shahneen Sandhu, Rodney Hicks

Conference Proceedings  |  2019  |  JOURNAL OF NUCLEAR MEDICINE

PATTERNS AND PREVALENCE OF IMMUNE-RELATED ADVERSE EVENTS AS DETECTED WITH FDG PET/CT IN PATIENTS TREATED WITH COMBINED CTLA-4 AND PD-1 INHIBITOR AS FIRST-LINE THERAPY FOR ADVANCED MELANOMA

A Iravani, MM Osman, MS Hofman, A Weppler, G Au-Yeung, S Sandhu, RJ Hicks

Conference Proceedings  |  2019  |  INTERNAL MEDICINE JOURNAL

19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes

Diar Aziz, Dariush Etemadmoghadam, C Elizabeth Caldon, George Au-Yeung, Niantao Deng, Ryan Hutchinson, David Bowtell, Paul Waring

Journal article  |  2018  |  Gynecologic Oncology

COMPARING THE IMPACT OF DOSE REDUCTIONS/ DELAYS ON OVARIAN CANCER OUTCOMES USING THREE WEEKLY OR DOSE DENSE CARBOPLATIN/ PACLITAXEL REGIMENS IN THE NATIONAL PROSPECTIVE OPAL COHORT

L Mileshkin, T Sivakumaran, P Grant, L Na, M Friedlander, P Webb, G Au-Yeung

Conference Proceedings  |  2018  |  INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

PHASE 2 STUDY OF IV VINORELBINE IN RELAPSED PLATINUM RESISTANT/ REFRACTORY C5 HIGH GRADE SEROUS, ENDOMETRIOID OR UNDIFFERENTIATED PRIMARY PERITONEUM, FALLOPIAN TUBE OR OVARIAN CANCER

V Heong, J Ye, G Au Yeung, TZ Tan, D Bowtell, R Huang, M Linda, D Tan

Conference Proceedings  |  2018  |  INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Australian Ovarian Cancer Assortment Trial-Allocating ovarian cancer patients into clinical trials based on molecular profiling.

Olga Kondrashova, George Au-Yeung, Leakhena Leas, Gwo-Yaw Ho, Sebastian Lunke, Kathryn Alsop, Clare Scott, Anne Hamilton, Sumitra Ananda, Alison Freimund, Michael Quinn, Orla McNally, Nadia Traficante, Tiffany Cowie, Matthew Wakefield, Arthur Hsu, Alex Dobrovic, Michael Christie, Graham Taylor, David Bowtell, et al.

Conference Proceedings  |  2018  |  CLINICAL CANCER RESEARCH

Comparing the impact of dose reductions and delays on ovarian cancer patient outcomes with three-weekly versus dose dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort.

Tharani Sivakumaran, Linda R Mileshkin, Peter T Grant, Michael Friedlander, Penelope M Webb, George Au-Yeung

Conference Proceedings  |  2018  |  Journal of Clinical Oncology

Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS)

George Au-Yeung, Penelope M Webb, Anna DeFazio, Sian Fereday, Mathias Bressel, Linda Mileshkin

Journal article  |  2014  |  Gynecologic Oncology

Radiation with cisplatin or carboplatin for locally advanced cervix cancer: The experience of a tertiary cancer centre

George Au-Yeung, Linda Mileshkin, David M Bernshaw, Srinivas Kondalsamy-Chennakesavan, Danny Rischin, Kailash Narayan

Journal article  |  2013  |  Journal of Medical Imaging and Radiation Oncology